Lupin has launched Flucytosine capsules USP, 250 mg and 500 mg, having received an approval from the United States Food and Drug Administration (USFDA), which are AB rated generic equivalent of Valeant Pharmaceuticals International Inc’s ANCOBON Capsules, 250 mg and 500 mg, indicated for the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus.
Flucytosine Capsules USP, 250 mg and 500 mg had annual sales of approximately $48 million in the US, as per IMS MAT October 2017.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
